V419

BIOLOGICAL4 trials

Sponsors

Merck Sharp & Dohme LLC, MCM Vaccines B.V.

Conditions

Bacterial InfectionsNeisseria MeningitidisVirus Diseases

Phase 3

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

CompletedNCT01337167

Merck Sharp & Dohme LLCBacterial Infections, Virus Diseases

Start: 2011-04-19End: 2013-05-09Updated: 2018-11-15

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

CompletedNCT01340937

Merck Sharp & Dohme LLCBacterial Infections, Virus Diseases

Start: 2011-05-10End: 2013-07-26Updated: 2018-11-15

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

CompletedNCT01341639

MCM Vaccines B.V.Bacterial Infections, Virus Diseases

Start: 2011-05-26End: 2013-03-13Updated: 2019-04-30

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

CompletedNCT01553279

MCM Vaccines B.V.Bacterial Infections, Neisseria Meningitidis, Virus Diseases

Start: 2012-03-30End: 2013-09-27Updated: 2019-03-28

Related Papers

A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.

2017-02-0122 citations

Lot-to-lot Consistency, Safety, Tolerability and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants.

2017-02-0116 citations

1112A Phase III Study of the Safety, Tolerability and Immunogenicity of an Investigational Combination Vaccine against Diphtheria, Tetanus, Pertussis (DTaP5), Polio (IPV), Haemophilus influenzae type b (Hib; PRP-OMPC), and Hepatitis B (HepB) in US Infants

Open Forum Infectious Diseases2014-01-01